Clinical Trials

Avalon GloboCare Corp., a clinical-stage global developer of cell-based technologies and therapeutics, announced it has successfully completed Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001 (National Institute of Health clinical trial...

Samsung Bioepis  announced the initiation of Phase 3 clinical trial for SB15, the company's proposed biosimilar referencing Eylea® (aflibercept). The Phase 3 clinical trial for SB15 (aflibercept) is a randomised, double-masked, parallel group, multicenter study to compare the efficacy,...

AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating genetic disease. Selumetinib is co-developed and co-commercialised with MSD Inc., Kenilworth, N.J., US (MSD: known...

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has deployed the Xcellerate® COVID-19 solution as part of its award-winning Xcellerate platform. Covance has developed a...

Bharat Biotech has successfully developed COVAXIN™, India’s 1stvaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) -National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech....

Zealand Pharma announced that the first patient has been dosed in a Phase 2 clinical trial of the long-acting GLP-1/glucagon dual agonist BI 456906, which Zealand has licensed to Boehringer Ingelheim. As part of the license agreement, Zealand will...

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials. Under...